Par reaches settlement with Sanofi-Aventis for Eloxatin generic

WOODCLIFF LAKE, N.J. Par Pharmaceuticals has reached a settlement with Sanofi-Aventis in a case concerning a generic cancer drug, Par announced Monday.

Par said it settled patent litigation with Sanofi over its version of Sanofi’s and Debiopharm’s injectable colorectal cancer drug Eloxatin (oxaliplatin).

Under the agreement, Par can begin selling its version of Eloxatin in August 2012. The drug had sales of $993 million in 2009, according to IMS Health.